JP2019516719A5 - - Google Patents

Download PDF

Info

Publication number
JP2019516719A5
JP2019516719A5 JP2018560595A JP2018560595A JP2019516719A5 JP 2019516719 A5 JP2019516719 A5 JP 2019516719A5 JP 2018560595 A JP2018560595 A JP 2018560595A JP 2018560595 A JP2018560595 A JP 2018560595A JP 2019516719 A5 JP2019516719 A5 JP 2019516719A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
group
guanosine
mrna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018560595A
Other languages
English (en)
Japanese (ja)
Other versions
JP7114485B2 (ja
JP2019516719A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/033398 external-priority patent/WO2017201328A1/en
Publication of JP2019516719A publication Critical patent/JP2019516719A/ja
Publication of JP2019516719A5 publication Critical patent/JP2019516719A5/ja
Priority to JP2022119527A priority Critical patent/JP2022136230A/ja
Application granted granted Critical
Publication of JP7114485B2 publication Critical patent/JP7114485B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018560595A 2016-05-18 2017-05-18 ファブリー病の治療のためのα-ガラクトシダーゼAをコードするポリヌクレオチド Active JP7114485B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022119527A JP2022136230A (ja) 2016-05-18 2022-07-27 ファブリー病の治療のためのα-ガラクトシダーゼAをコードするポリヌクレオチド

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662338354P 2016-05-18 2016-05-18
US62/338,354 2016-05-18
PCT/US2017/033398 WO2017201328A1 (en) 2016-05-18 2017-05-18 POLYNUCLEOTIDES ENCODING α-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022119527A Division JP2022136230A (ja) 2016-05-18 2022-07-27 ファブリー病の治療のためのα-ガラクトシダーゼAをコードするポリヌクレオチド

Publications (3)

Publication Number Publication Date
JP2019516719A JP2019516719A (ja) 2019-06-20
JP2019516719A5 true JP2019516719A5 (cg-RX-API-DMAC7.html) 2020-06-25
JP7114485B2 JP7114485B2 (ja) 2022-08-08

Family

ID=59021568

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018560595A Active JP7114485B2 (ja) 2016-05-18 2017-05-18 ファブリー病の治療のためのα-ガラクトシダーゼAをコードするポリヌクレオチド
JP2022119527A Pending JP2022136230A (ja) 2016-05-18 2022-07-27 ファブリー病の治療のためのα-ガラクトシダーゼAをコードするポリヌクレオチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022119527A Pending JP2022136230A (ja) 2016-05-18 2022-07-27 ファブリー病の治療のためのα-ガラクトシダーゼAをコードするポリヌクレオチド

Country Status (6)

Country Link
US (5) US20190000932A1 (cg-RX-API-DMAC7.html)
EP (2) EP3896164A1 (cg-RX-API-DMAC7.html)
JP (2) JP7114485B2 (cg-RX-API-DMAC7.html)
AU (1) AU2017266932B2 (cg-RX-API-DMAC7.html)
CA (1) CA3024507A1 (cg-RX-API-DMAC7.html)
WO (1) WO2017201328A1 (cg-RX-API-DMAC7.html)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
EP3092049A1 (en) 2014-01-08 2016-11-16 Flodesign Sonics Inc. Acoustophoresis device with dual acoustophoretic chamber
RS66380B1 (sr) 2014-04-23 2025-02-28 Modernatx Inc Vakcine nukleinske kiseline
KR102702200B1 (ko) 2014-12-22 2024-09-02 코덱시스, 인코포레이티드 인간 알파-갈락토시다제 변이체
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
EP4218805A1 (en) 2015-07-21 2023-08-02 ModernaTX, Inc. Infectious disease vaccines
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
WO2017020026A1 (en) 2015-07-30 2017-02-02 Modernatx, Inc. Concatemeric peptide epitopes rnas
WO2017031232A1 (en) 2015-08-17 2017-02-23 Modernatx, Inc. Methods for preparing particles and related compositions
ES2910425T3 (es) 2015-09-17 2022-05-12 Modernatx Inc Compuestos y composiciones para la administración intracelular de agentes terapéuticos
JP6921833B2 (ja) 2015-10-22 2021-08-18 モデルナティーエックス, インコーポレイテッド ヒトサイトメガロウイルスワクチン
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
EP4349405A3 (en) 2015-10-22 2024-06-19 ModernaTX, Inc. Respiratory virus vaccines
TN2018000152A1 (en) 2015-10-22 2019-10-04 Modernatx Inc Nucleic acid vaccines for varicella zoster virus (vzv)
WO2017099823A1 (en) * 2015-12-10 2017-06-15 Modernatx, Inc. Compositions and methods for delivery of therapeutic agents
EP4036079B1 (en) 2015-12-22 2025-11-19 ModernaTX, Inc. Compounds and compositions for intracellular delivery of agents
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
WO2017201342A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding jagged1 for the treatment of alagille syndrome
CA3024507A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding .alpha.-galactosidase a for the treatment of fabry disease
CA3036831A1 (en) 2016-09-14 2018-03-22 Modernatx, Inc. High purity rna compositions and methods for preparation thereof
EP3528821A4 (en) 2016-10-21 2020-07-01 ModernaTX, Inc. HUMAN CYTOMEGALOVIRUS VACCINE
EP3538146A4 (en) 2016-11-11 2020-07-15 ModernaTX, Inc. INFLUENZA VACCINE
US11103578B2 (en) 2016-12-08 2021-08-31 Modernatx, Inc. Respiratory virus nucleic acid vaccines
US11384352B2 (en) 2016-12-13 2022-07-12 Modernatx, Inc. RNA affinity purification
WO2018170336A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Lipid nanoparticle formulation
US11576961B2 (en) 2017-03-15 2023-02-14 Modernatx, Inc. Broad spectrum influenza virus vaccine
RS63953B1 (sr) 2017-03-15 2023-02-28 Modernatx Inc Jedinjenje i kompozicije za intracelularnu isporuku terapeutskih sredstava
AU2018234814B2 (en) 2017-03-15 2022-06-30 Modernatx, Inc. Crystal forms of amino lipids
WO2018170270A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Varicella zoster virus (vzv) vaccine
US11752206B2 (en) 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine
US11464848B2 (en) 2017-03-15 2022-10-11 Modernatx, Inc. Respiratory syncytial virus vaccine
MA47790A (fr) 2017-03-17 2021-05-05 Modernatx Inc Vaccins à base d'arn contre des maladies zoonotiques
CA3056812C (en) * 2017-03-23 2022-11-29 Medicago Inc. Norovirus fusion proteins and vlps comprising norovirus fusion proteins
JP2020513824A (ja) 2017-03-24 2020-05-21 キュアバック アーゲー Crispr関連タンパク質をコードする核酸、及びその使用
EP3607074A4 (en) 2017-04-05 2021-07-07 Modernatx, Inc. REDUCTION OR ELIMINATION OF IMMUNE RESPONSES TO NON-INTRAVENOUS THERAPEUTIC PROTEINS, FOR EXAMPLE SUBCUTANEOUSLY
WO2018232120A1 (en) 2017-06-14 2018-12-20 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
EP3638215A4 (en) 2017-06-15 2021-03-24 Modernatx, Inc. RNA FORMULATIONS
EP3668971B8 (en) 2017-08-18 2024-05-29 ModernaTX, Inc. Rna polymerase variants
EP3668977A4 (en) 2017-08-18 2021-04-21 Modernatx, Inc. HPLC ANALYTICAL PROCESSES
EP3668979A4 (en) 2017-08-18 2021-06-02 Modernatx, Inc. METHOD OF HPLC ANALYSIS
CA3073211A1 (en) 2017-08-31 2019-03-07 Modernatx, Inc. Methods of making lipid nanoparticles
WO2019055807A1 (en) 2017-09-14 2019-03-21 Modernatx, Inc. RNA VACCINES AGAINST ZIKA VIRUS
JP2021507561A (ja) 2017-12-14 2021-02-22 フロデザイン ソニックス, インク.Flodesign Sonics, Inc. 音響トランスデューサドライバ及びコントローラ
WO2019126144A1 (en) 2017-12-22 2019-06-27 North Carolina State University Polymeric fluorophores, compositions comprising the same, and methods of preparing and using the same
US11911453B2 (en) 2018-01-29 2024-02-27 Modernatx, Inc. RSV RNA vaccines
EP3746052A1 (en) * 2018-01-30 2020-12-09 Modernatx, Inc. Compositions and methods for delivery of agents to immune cells
US12162994B2 (en) 2018-03-02 2024-12-10 Sigilon Therapeutics, Inc. Biocompatible hydrogel capsules and process for preparing same
IL277713B2 (en) 2018-04-04 2024-09-01 Sigilon Therapeutics Inc Implantable particles and related methods
EP3853202A1 (en) 2018-09-19 2021-07-28 ModernaTX, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
CN112996854B (zh) 2018-09-19 2024-08-30 摩登纳特斯有限公司 高纯度peg脂质和其用途
EP3852732A1 (en) 2018-09-19 2021-07-28 ModernaTX, Inc. Peg lipids and uses thereof
WO2020061457A1 (en) 2018-09-20 2020-03-26 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
CN113544268A (zh) 2018-12-20 2021-10-22 科德克希思公司 人类α半乳糖苷酶变体
JP7716338B2 (ja) * 2019-01-04 2025-07-31 サンガモ セラピューティクス, インコーポレイテッド ファブリー病の処置のための方法及び組成物
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
MA55037A (fr) 2019-02-20 2021-12-29 Modernatx Inc Variants d'arn polymérase pour le coiffage co-transcriptionnel
US11851694B1 (en) 2019-02-20 2023-12-26 Modernatx, Inc. High fidelity in vitro transcription
KR20210149727A (ko) 2019-03-11 2021-12-09 모더나티엑스, 인크. 유가식(fed-batch) 시험관내 전사 공정
WO2020190750A1 (en) 2019-03-15 2020-09-24 Modernatx, Inc. Hiv rna vaccines
EP3946433A4 (en) * 2019-03-27 2023-01-18 Sigilon Therapeutics, Inc. COMPOSITIONS, DEVICES AND METHODS FOR THE TREATMENT OF FABRY'S DISEASE
US20230086537A1 (en) * 2019-05-07 2023-03-23 Modernatx, Inc. Differentially expressed immune cell micrornas for regulation of protein expression
US20220296517A1 (en) * 2019-08-07 2022-09-22 Moderna TX, Inc. Compositions and methods for enhanced delivery of agents
AR120080A1 (es) 2019-09-19 2022-02-02 Modernatx Inc Compuestos lipídicos de cola ramificada y composiciones para la administración intracelular de agentes terapéuticos
IL295818A (en) * 2020-02-28 2022-10-01 Codexis Inc Human alpha-galactosidase variants
WO2021183895A1 (en) * 2020-03-13 2021-09-16 Biomarin Pharmaceutical Inc. Treatment of fabry disease with aav gene therapy vectors
CN113874507A (zh) 2020-04-09 2021-12-31 苏州艾博生物科技有限公司 冠状病毒的核酸疫苗
CA3178455A1 (en) 2020-04-09 2021-10-14 Suzhou Abogen Biosciences Co., Ltd. Lipid nanoparticle composition
KR102314642B1 (ko) * 2020-04-17 2021-10-20 재단법인 아산사회복지재단 파브리 병 진단용 바이오 마커 및 이의 용도
KR102813425B1 (ko) 2020-04-22 2025-05-28 바이오엔테크 에스이 코로나바이러스 백신
WO2021222094A1 (en) 2020-04-27 2021-11-04 4D Molecular Therapeutics Inc. Codon optimized gla genes and uses thereof
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
MX2023004371A (es) 2020-10-14 2023-07-26 George Mason Res Foundation Inc Lípidos ionizables, y métodos de fabricación y uso de los mismos.
US12329811B2 (en) 2021-01-11 2025-06-17 Modernatx, Inc. Seasonal RNA influenza virus vaccines
CA3208153A1 (en) * 2021-01-14 2022-07-21 Spark Therapeutics, Inc. Compositions and methods for treating fabry disease
NL2027654B1 (en) * 2021-02-08 2022-09-09 Nutcracker Therapeutics Inc Methods for manufacturing a syntetic template
US20220363937A1 (en) 2021-05-14 2022-11-17 Armstrong World Industries, Inc. Stabilization of antimicrobial coatings
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
US20230340077A1 (en) * 2021-12-01 2023-10-26 Luyef Biotechnologies Inc. Production of myoglobin from trichoderma using a feeding media
KR20240148846A (ko) * 2022-01-20 2024-10-11 오하이오 스테이트 이노베이션 파운데이션 지질 화합물을 포함하는 조성물과 이의 제조 및 사용 방법
CN114672501B (zh) * 2022-05-27 2022-08-23 珠海丽凡达生物技术有限公司 一种mRNA、药物组合物及其应用
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5082767A (en) 1989-02-27 1992-01-21 Hatfield G Wesley Codon pair utilization
WO2000018778A1 (en) 1998-09-29 2000-04-06 Phylos, Inc. Synthesis of codon randomized nucleic acids
US20090017533A1 (en) 1998-09-29 2009-01-15 Shire Human Genetic Therapies, Inc., A Delaware Corporation Optimized messenger rna
AU2002215389A1 (en) 2000-10-11 2002-08-28 Transkaryotic Therapies, Inc. Optimized messenger rna
EP2305699B1 (de) 2001-06-05 2014-08-13 CureVac GmbH Stabilisierte mRNA mit erhöhtem G/C-Gehalt und optimierter Codon Usage für die Impfung gegen Schlafkrankheit, Leishmaniose und Toxoplasmose
CA2462144C (en) 2001-09-28 2016-09-20 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Micro-rna molecules
US20040005600A1 (en) 2002-04-01 2004-01-08 Evelina Angov Method of designing synthetic nucleic acid sequences for optimal protein expression in a host cell
DE10260805A1 (de) 2002-12-23 2004-07-22 Geneart Gmbh Verfahren und Vorrichtung zum Optimieren einer Nucleotidsequenz zur Expression eines Proteins
WO2005013901A2 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
CN101495504A (zh) 2005-06-30 2009-07-29 阿切埃米克斯有限公司 用于生产全2’-修饰的核酸转录产物的材料和方法
US8101385B2 (en) 2005-06-30 2012-01-24 Archemix Corp. Materials and methods for the generation of transcripts comprising modified nucleotides
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
US20080046192A1 (en) 2006-08-16 2008-02-21 Richard Lathrop Polypepetide-encoding nucleotide sequences with refined translational kinetics and methods of making same
AU2007337810B2 (en) 2006-12-22 2014-02-13 Archemix Corp. Materials and methods for the generation of transcripts comprising modified nucleotides
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
KR101541935B1 (ko) 2007-09-26 2015-08-05 인트렉손 코포레이션 합성 5'utr, 발현 벡터, 및 전이유전자 발현의 증가방법
SG188866A1 (en) 2007-12-11 2013-04-30 Scripps Research Inst Compositions and methods related to mrna translational enhancer elements
US7561973B1 (en) 2008-07-31 2009-07-14 Dna Twopointo, Inc. Methods for determining properties that affect an expression property value of polynucleotides in an expression system
US8126653B2 (en) 2008-07-31 2012-02-28 Dna Twopointo, Inc. Synthetic nucleic acids for expression of encoded proteins
PL215513B1 (pl) 2008-06-06 2013-12-31 Univ Warszawski Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka
US8401798B2 (en) 2008-06-06 2013-03-19 Dna Twopointo, Inc. Systems and methods for constructing frequency lookup tables for expression systems
LT2440183T (lt) 2009-06-10 2018-08-10 Arbutus Biopharma Corporation Patobulinta lipido kompozicija
US20110082055A1 (en) 2009-09-18 2011-04-07 Codexis, Inc. Reduced codon mutagenesis
WO2012075040A2 (en) 2010-11-30 2012-06-07 Shire Human Genetic Therapies, Inc. mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
US9999673B2 (en) 2011-01-11 2018-06-19 Alnylam Pharmaceuticals, Inc. PEGylated lipids and their use for drug delivery
WO2012135805A2 (en) 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
LT2717893T (lt) 2011-06-08 2019-08-12 Translate Bio, Inc. Lipidų nanodalelių kompozicijos ir mrnr pristatymo būdai
DK3336082T3 (da) 2011-06-08 2020-04-27 Translate Bio Inc Spaltelige lipider
WO2013016058A1 (en) * 2011-07-22 2013-01-31 Merck Sharp & Dohme Corp. Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery
EP2755986A4 (en) 2011-09-12 2015-05-20 Moderna Therapeutics Inc MANIPULATED NUCLEIC ACIDS AND METHOD OF APPLICATION THEREFOR
US9428535B2 (en) 2011-10-03 2016-08-30 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
BR112014019431A8 (pt) 2012-02-07 2017-07-11 Global Bio Therapeutics Usa Inc Método compartimentalizado de distribuição de ácido nucleico e composições e usos desses
WO2013120497A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
ES2868174T3 (es) 2012-03-29 2021-10-21 Translate Bio Ma Inc Lípidos catiónicos ionizables
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
EP2834260A4 (en) 2012-04-02 2016-08-10 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES FOR THE PREPARATION OF MEMBRANE PROTEINS
US10245229B2 (en) 2012-06-08 2019-04-02 Translate Bio, Inc. Pulmonary delivery of mRNA to non-lung target cells
EP2885419A4 (en) 2012-08-14 2016-05-25 Moderna Therapeutics Inc ENZYMES AND POLYMERASES FOR RNA SYNTHESIS
WO2014089486A1 (en) 2012-12-07 2014-06-12 Shire Human Genetic Therapies, Inc. Lipidic nanoparticles for mrna delivering
EP2931319B1 (en) 2012-12-13 2019-08-21 ModernaTX, Inc. Modified nucleic acid molecules and uses thereof
EP3434774A1 (en) * 2013-01-17 2019-01-30 ModernaTX, Inc. Signal-sensor polynucleotides for the alteration of cellular phenotypes
WO2014164253A1 (en) 2013-03-09 2014-10-09 Moderna Therapeutics, Inc. Heterologous untranslated regions for mrna
KR20150127582A (ko) 2013-03-14 2015-11-17 샤이어 휴먼 지네틱 테라피즈 인크. 4''-티오 개질된 뉴클레오티드를 갖는 리보핵산 및 관련 방법
PL4332576T3 (pl) 2013-03-15 2025-09-08 Translate Bio, Inc. Synergistyczne wzmocnienie dostarczania kwasów nukleinowych poprzez formulacje zmieszane
US10342760B2 (en) * 2013-03-15 2019-07-09 The University Of British Columbia Lipid nanoparticles for transfection and related methods
EP3052106A4 (en) * 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
TWI793159B (zh) * 2013-10-23 2023-02-21 美商健臻公司 重組醣蛋白及其用途
US10821175B2 (en) 2014-02-25 2020-11-03 Merck Sharp & Dohme Corp. Lipid nanoparticle vaccine adjuvants and antigen delivery systems
RS66380B1 (sr) * 2014-04-23 2025-02-28 Modernatx Inc Vakcine nukleinske kiseline
IL298516B2 (en) * 2014-06-25 2025-03-01 Acuitas Therapeutics Inc Novel lipids and lipid nanoparticle compositions for nucleic acid delivery
EP3247363A4 (en) * 2015-01-21 2018-10-03 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
EP4219532A3 (en) 2015-06-05 2023-08-16 Dana-Farber Cancer Institute, Inc. Compositions and methods for transient gene therapy with enhanced stability
ES2910425T3 (es) 2015-09-17 2022-05-12 Modernatx Inc Compuestos y composiciones para la administración intracelular de agentes terapéuticos
WO2017153936A1 (en) 2016-03-10 2017-09-14 Novartis Ag Chemically modified messenger rna's
EP3452101A2 (en) 2016-05-04 2019-03-13 CureVac AG Rna encoding a therapeutic protein
CA3024507A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding .alpha.-galactosidase a for the treatment of fabry disease
JP7560946B2 (ja) 2016-11-10 2024-10-03 トランスレイト バイオ, インコーポレイテッド メッセンジャーrnaの皮下送達

Similar Documents

Publication Publication Date Title
JP2019516719A5 (cg-RX-API-DMAC7.html)
JP7789819B2 (ja) 核酸のデリバリーのための新規脂質および脂質ナノ粒子製剤
JP2018530560A5 (cg-RX-API-DMAC7.html)
TWI672314B (zh) 反義核酸
JP6525455B2 (ja) 免疫賦活活性を有するオリゴヌクレオチド含有複合体及びその用途
JP2022136230A5 (cg-RX-API-DMAC7.html)
JP2021512090A (ja) 免疫細胞に薬剤を送達するための組成物及び方法
EP4026568A1 (en) Lyophilization of rna
RU2017139121A (ru) Композиции для модулирования экспрессии c9orf72
EP3849589A1 (en) Methods and compositions for treating cancer using mrna therapeutics
JP2020503009A5 (cg-RX-API-DMAC7.html)
JP2019504002A5 (cg-RX-API-DMAC7.html)
JP2016533761A5 (cg-RX-API-DMAC7.html)
JP2017532038A5 (cg-RX-API-DMAC7.html)
JP2019511491A5 (cg-RX-API-DMAC7.html)
JP2014518612A5 (cg-RX-API-DMAC7.html)
JP2020143065A (ja) B型肝炎およびd型肝炎ウイルス感染の治療のための方法
JP2019535723A5 (cg-RX-API-DMAC7.html)
JP2021500016A5 (cg-RX-API-DMAC7.html)
US20210355490A1 (en) Sting-dependent activators for treatment of disease
WO2019035901A1 (en) COMPOSITIONS AND METHODS FOR STING PROTEIN MODULATION
RU2019101298A (ru) Антисмысловые олигонуклеотиды для модулирования экспрессии htra1
JP2011518168A5 (cg-RX-API-DMAC7.html)
JP2013537404A5 (cg-RX-API-DMAC7.html)
US20190233824A1 (en) Pd-1 specific aptamers